微链 rna 的共聚焦成像和模式识别受体在负感 rna 病毒感染中的应用
2019年1月26日
7.5K 次观看
在 rna 病毒复制过程中产生的双链 rna 可以通过模式识别受体来识别, 从而诱导先天免疫反应。对于负感 rna 病毒, 低水平 dsrna 和 prr 之间的相互作用仍不清楚。我们开发了一种共聚焦显微镜方法, 用于在单个细胞中显示腺病毒 dsrna 和 prr。
传统的双链RNA检测检测通常不够灵敏，无法检测在负感RNA病毒感染中形成的双链RNA。因此，双链RNA和宿主模式识别受体之间的相互作用对于这些病毒来说基本上仍然难以捉摸。利用该协议，我们能够可视化和描述病毒核蛋白、双链RNA和在单细胞水平上宿主的PRR对负感RNA病毒的相互作用。这是一种多路复用检测，允许在单个细胞中同时染色双链RNA和两个病毒或宿主蛋白靶点。与RNA-FISH测定不同，该技术与RNA序列无关，通常与蛋白质靶点抗体检测相容。在感染前24小时开始，将20万个人类肺上皮 A549细胞播种到12孔板中的聚-D-Lysine涂层玻璃盖上，并在37孔生长
查看完整文字稿并访问数千部科学视频
概览
本研究调查了模式识别受体（PRRs）识别RNA病毒复制过程中产生的双链RNA（dsRNA）以诱导先天免疫反应的机制。重点是针对负义RNA病毒，其中低水平dsRNA与PRRs之间的相互作用尚未完全了解。已开发了一种共聚焦显微镜方法来可视化单个细胞中的竞技场病毒dsRNA和PRRs。
关键研究组成部分
科学领域
- 神经科学
- 免疫学
- 病毒学
背景
- 双链RNA是RNA病毒复制的副产品。
- 模式识别受体在先天免疫反应中起着至关重要的作用。
- 负义RNA病毒中dsRNA与PRRs之间的相互作用尚不清楚。
- 可视化dsRNA和PRRs可以增强对病毒免疫逃逸的理解。
研究目的
- 阐明负义RNA病毒中dsRNA与PRRs之间的相互作用。
- 开发一种方法来可视化这些相互作用在单个细胞中的过程。
- 为理解RNA病毒的先天免疫反应做出贡献。
使用的方法
- 用于可视化dsRNA和PRRs的共聚焦显微镜。
- 用于评估免疫反应的细胞测定。
- 分析病毒复制期间dsRNA水平。
- 与不同RNA病毒的比较研究。
主要结果
- 成功可视化单个细胞中的竞技场病毒dsRNA和PRRs。
- 识别dsRNA与PRRs之间的特定相互作用。
- 洞察dsRNA触发的免疫反应机制。
- 阐明dsRNA在病毒发病机制中的作用。
结论
- 开发的共聚焦显微镜方法对于研究dsRNA和PRRs相互作用是有效的。
- 理解这些相互作用可能导致针对RNA病毒的新疗法。
- 这项研究为病毒免疫学的更广泛领域做出了贡献。
常见问题
dsRNA在病毒感染中的意义是什么？
dsRNA是病毒复制的关键指标，可以触发免疫反应。
共聚焦显微镜如何帮助这项研究？
它允许在细胞水平上可视化dsRNA和PRRs相互作用。
什么是模式识别受体？
PRRs是识别病原体并激活免疫反应的蛋白质。
为什么关注负义RNA病毒？
与正义RNA病毒相比，它们的免疫逃逸机制较少被了解。
这项研究有什么潜在应用？
它可能导致新的抗病毒疗法并增强疫苗开发。
Executive Industry Relevance
Visualizing low-abundance double-stranded RNA (dsRNA) in negative-sense RNA virus infection addresses a critical gap in understanding innate immune activation and viral immune evasion. This capability supports target validation and mechanistic de-risking in antiviral discovery by enabling direct observation of pattern recognition receptor (PRR) engagement with viral replicative intermediates. The method enhances predictive confidence in early-stage target selection for arenavirus and related pathogens, informing portfolio prioritization in high-containment pathogen programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by visualizing dsRNA-PRR interactions at single-cell resolution in pathogenic virus models.
- Operational Value: Provides a sensitive, sequence-independent detection method compatible with multiplexed protein staining for pathway clarification.
- Predictive Value: Supports biological de-risking of PRR targets by confirming ligand engagement in relevant infection contexts.
Screening & Assay Development
- Assay Readiness: Generates quantitative, spatially resolved readouts of dsRNA and PRR colocalization for assay standardization.
- Screening Relevance: Prepares validated biological systems for downstream compound screening by establishing baseline immune activation metrics.
- Platform Utility: Compatible with antibody-based detection, enabling reuse across viral targets and host proteins in imaging workflows.
Translational & Preclinical Research
- Translational Continuity: Bridges discovery observations to preclinical validation by mapping dsRNA distribution and PRR recruitment in disease-relevant systems.
- Mechanistic Insight: Clarifies spatial and temporal dynamics of innate immune signaling, informing biomarker selection for pathway modulation.
- Risk-Adjusted Advancement: Enables data-driven go/no-go decisions based on visual confirmation of target engagement in high-pathogenicity models.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target hypothesis testing through lead identification to preclinical validation, particularly for immunomodulatory antivirals targeting PRR pathways.
- Discovery Biology: Supports hypothesis testing of PRR agonist/antagonist mechanisms by visualizing dsRNA as the endogenous ligand in infected cells.
- Screening: Delivers reproducible, quantitative imaging outputs that enable comparison of compound effects on dsRNA-PRR interactions.
- Analytics: Provides multiplexed fluorescence readouts (dsRNA, viral protein, PRR) for high-content analysis of immune activation states.
- Translational Research: Connects in vitro observations to preclinical continuity by confirming PRR activation in primary or stem-cell-derived lung epithelial models.
- Enterprise Reuse: Establishes a standardized imaging platform applicable to multiple negative-sense RNA viruses and host targets beyond arenaviruses.
Operational & Enterprise Impact
- Scientific Value: Increases target validation confidence by reducing mechanistic ambiguity in PRR-ligand interactions.
- Operational Value: Enhances assay reproducibility and scalability through standardized confocal protocols and sensitive dsRNA detection.
- Strategic Value: Improves go/no-go decision quality by providing direct visual evidence of pathway modulation, reducing late-stage attrition.
- Portfolio Impact: Enables risk-adjusted prioritization of immunomodulatory candidates based on confirmed target engagement in pathogenic virus contexts.
Implementation Considerations
- Requires expertise in confocal microscopy, immunofluorescence staining, and biosafety-level-appropriate virology techniques.
- Dependent on access to high-sensitivity dsRNA antibodies (e.g., 9D5 clone) and compatible fluorescence imaging infrastructure.
- Necessitates standardization across laboratories for consistent dsRNA signal quantification and colocalization analysis.
- Must account for cell model variability (e.g., A549 vs. primary airway epithelium) in dsRNA production and PRR expression levels.
- Practical limitations include potential antibody cross-reactivity and the need for optimization in high-containment (BSL-3/BSL-4) settings.
Biopharma FAQs
Why does null hypothesis testing matter for target validation of PRR agonists?
Null hypothesis testing establishes whether observed dsRNA-PRR colocalization exceeds random chance, providing statistical rigor for target validation. This ensures that therapeutic hypotheses about PRR activation are supported by significant, reproducible imaging data rather than stochastic variation. In early discovery, this statistical foundation reduces false-positive target selection and improves predictive confidence in pathway modulation strategies.
How does independent variable isolation fit the antiviral discovery pipeline?
Isolating dsRNA as the independent variable allows researchers to attribute changes in PRR recruitment or signaling directly to viral ligand presence, excluding confounding factors. This approach supports mechanistic de-risking by confirming that observed immune effects are driven by dsRNA engagement rather than off-target compound effects. In screening campaigns, this isolation enables clean structure-activity relationships for immunomodulators targeting PRR pathways.
What quantitative dependent variable measurements enable hit selection in immunomodulator screening?
Quantitative measurements such as dsRNA intensity, PRR fluorescence intensity, and colocalization coefficients serve as dependent variables for assessing compound effects on immune activation. These metrics enable objective comparison across treatment conditions, identifying hits that significantly modulate PRR-dsRNA interactions. Threshold-based analysis of these readouts supports prioritization of compounds with desired immunomodulatory profiles in primary screens.
Why do replication requirements matter for cross-functional collaboration in target validation?
Replication across independent experiments and cell lines ensures that dsRNA-PRR interaction observations are robust and not artifacts of specific conditions, building confidence for cross-functional teams. Consistent replication enables chemistry, biology, and translational teams to align on target validation data, reducing misinterpretation in downstream decision-making. This reproducibility is essential for generating defensible data packages for IND-enabling studies.
What statistical analysis capabilities are required before implementing this imaging assay in drug discovery?
Implementation requires capability for quantitative image analysis, including intensity thresholding, colocalization statistics (e.g., Pearson’s coefficient), and hypothesis testing (e.g., t-tests or ANOVA) across experimental groups. Teams must establish power analysis to determine replicate numbers needed for detecting biologically relevant changes in dsRNA-PRR interactions. Access to bioinformatics or imaging analysis platforms supporting these statistical workflows is essential for scalable deployment.
